The Medsintez plant was selected as an OEM manufacturer upon monitoring of a number of Russian pharmaceutical enterprises. The customer was fully satisfied with the existing level of quality and technology standards at the enterprise, as well as equipment capabilities. Preparation of the production took from February to May and involved carrying out a transfer of analytical methods and technologies. According to A. Petrov, Medsintez's Chairman of the Board of Directors, the company assessed quality of the final product positively.   Now, the drug undergoes stability tests. The antibiotic will appear in the list of Medsintez drugs after the completion of tests and registration activities, by mid-2018.